You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C

  • Technology appraisal guidance
  • Reference number: TA200
  • Published:  22 September 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination - consultee and commentator comments on the ACD

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Department of Health

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - MSD/Schering Plough

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - NHS Quality Improvement Scotland

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Roche

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Nursing

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Pathologists

  • Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Southampton Health Technology Assessment Centre


This page was last updated: 12 August 2010

Back to top